A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma
Stopped In the context of the ongoing evaluation of our data, we have determined that there is no need to generate additional safety data at this time in the 1L mRCC pa
Conditions
Interventions
- DRUG: Atezolizumab
- DRUG: Bevacizumab
Sponsor
Hoffmann-La Roche